RAMM Pharma Corp.
RAMM
CNSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 710.80K | 748.00K | 882.20K | 852.90K | 707.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 710.80K | 748.00K | 882.20K | 852.90K | 707.50K |
| Cost of Revenue | 553.90K | 366.10K | 428.50K | 572.40K | 522.00K |
| Gross Profit | 156.90K | 381.90K | 453.70K | 280.60K | 185.60K |
| SG&A Expenses | 1.01M | 3.73M | 1.19M | 1.59M | 1.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 3.70K | 71.50K | 4.50K | 6.60K | 6.50K |
| Total Operating Expenses | 1.57M | 4.16M | 1.62M | 2.17M | 1.80M |
| Operating Income | -859.30K | -3.41M | -742.20K | -1.31M | -1.09M |
| Income Before Tax | -782.30K | -8.40M | -725.70K | -1.28M | -1.70M |
| Income Tax Expenses | -62.80K | 5.90K | -- | -- | -- |
| Earnings from Continuing Operations | -719.50K | -8.41M | -725.70K | -1.28M | -1.70M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -719.50K | -8.41M | -725.70K | -1.28M | -1.70M |
| EBIT | -859.30K | -3.41M | -742.20K | -1.31M | -1.09M |
| EBITDA | -728.10K | -3.25M | -561.50K | -1.13M | -862.60K |
| EPS Basic | -0.01 | -0.07 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | -0.02 | 0.00 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.07 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | -0.02 | 0.00 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 119.39M | 119.39M | 119.39M | 119.39M | 119.39M |
| Average Diluted Shares Outstanding | 119.39M | 119.39M | 119.39M | 119.39M | 119.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |